L26/P-295 Biopsy timing reflects embryo biology rather than genetic competence in good-quality blastocysts
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von L. Herrero Grassa und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does delaying trophectoderm biopsy to day 6 in good-quality blastocysts affect genetic outcome and the option to obtain a transferable embryo? Summary answer Delaying biopsy to day 6 in good-quality blastocysts does not impair genetic outcomes after adjustment for age and embryo quality. What is known already Preimplantation genetic testing for aneuploidies involves prolonged culture, trophectoderm biopsy and cryopreservation, making these cycles particularly sensitive to embryonic manipulation. Blastocysts biopsied on day-5 generally show higher euploidy and better clinical outcomes than those biopsied later; however, delayed biopsy often reflects developmental kinetics or technical constraints rather than suboptimal embryo quality. Whether postponing biopsy to day-6 in blastocysts of good quality compromises genetic outcomes remains controversial, and evidence addressing real-world laboratory decision-making is limited. Study design, size, duration Retrospective-observational study including 1,642 blastocysts biopsied between January 2023- September 2025. Embryos were classified into seven groups, combining embryo quality (ASEBIR), expansion and biopsy day, reproducing routine laboratory decision-making: expanded good-quality blastocysts biopsied on day-5 (G1=501), suboptimally expanded good-quality on day-5 (G2=215), medium-quality blastocysts biopsied on day-5 (G3=50), good-quality blastocysts biopsied on day 6 due to technical constraints on day-5 (G4=98), slow-developing good-quality blastocysts on day-6 (G5=448), slow-developing medium-quality blastocysts on day-6 (G6=240), day-7 (G7=90). Participants/materials, setting, methods Blastocysts originated from fresh autologous ICSI cycles, excluding male factor cycles. Genetic outcome was classified as euploid, mosaic or aneuploid. The option to obtain a transferable embryo was defined as a euploid or mosaic result. Multivariable logistic regression models adjusted for maternal age and embryo quality were used. Additionally, clinical pregnancy rate was analysed in 387 single euploid embryo transfers according to biopsy day during same period. Main results and the role of chance Mean maternal age was 39.0 ± 2.7 years. Overall, 468 embryos (28.5%) were euploid and 144 (8.8%). Maternal age was independently associated with a reduced probability of euploidy (OR 0.84 per year; p < 0.001) and with a reduced option to obtain a transferable embryo (OR 0.81 per year; p < 0.001). Suboptimal embryo quality significantly decreased the likelihood of obtaining a transferable embryo (OR 0.42; p < 0.001). The day of biopsy did not show an independent effect on euploidy or on the option to obtain a transferable embryo in any comparison between study groups. Specifically, no differences were observed between good-quality blastocysts biopsied on day-5 with suboptimal expansion (G2) and good-quality blastocysts biopsied on day-6 either due to technical constraints on day-5 (G4) or after delayed expansion (G5) (36.49% vs 36.08% transferable embryos; p = 0.94). In contrast, slow-developing blastocysts with medium quality biopsied on day-6 (G6) and day-7 medium-quality blastocysts (G8) showed lower euploidy rates overall compared with good-quality day-5 blastocysts. In the clinical analysis of SET, after adjustment for maternal age, day-6 biopsied euploid embryos showed a lower probability of clinical pregnancy compared with day-5 biopsied euploid embryos (30.1% vs 59.4%; OR 0.30; p < 0.0001). Limitations, reasons for caution Retrospetcive nature is a limitation, and clinical outcomes could not be stratified by embryo study group, limiting assessment of whether clinical differences persist after adjusting for embryo quality at transfer. This analysis represents the next planned step of the study. Wider implications of the findings Optimising biopsy timing according to embryo safety and developmental competence does not compromise genetic outcomes in good-quality blastocysts. In PGT-A cycles, where the ultimate goal is to obtain embryos suitable for transfer, these findings support embryo-centred, technically optimal biopsy strategies over forcing biopsy on day-5. Trial registration number No
Zitieren
APA
Grassa, L. H., Romero, L. C., Gonzalez, M. A., Jimenez, L. A., Roa, A. G., Martinez, R. B., Alcazar, Z. G., Salcedo, J. O., Garcia, A. B., & Morro, J. T. (2026). L26/P-295 Biopsy timing reflects embryo biology rather than genetic competence in good-quality blastocysts. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.631
Vancouver
Grassa LH, Romero LC, Gonzalez MA, Jimenez LA, Roa AG, Martinez RB, et al. L26/P-295 Biopsy timing reflects embryo biology rather than genetic competence in good-quality blastocysts. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.631
BibTeX
@article{Grassa2026,
author = {Grassa, L. Herrero and Romero, L. Cascales and Gonzalez, M. Aparicio and Jimenez, L. Arias and Roa, A. Garcia and Martinez, R. Bravo and Alcazar, Z. Garcia and Salcedo, J.A. Ortiz and Garcia, A. Bernabeu and Morro, J. Ten},
title = {L26/P-295 Biopsy timing reflects embryo biology rather than genetic competence in good-quality blastocysts},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.631}
}
EUVIMED